Imunon chair granted 4,410 shares at $1.91

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. Executive Chairman Michael H. Tardugno reported updated holdings of the company’s common stock. He received a grant of 4,410 shares of common stock at $1.91 per share, described as stock granted in lieu of cash for base salary, increasing his direct ownership to 64,396 shares. A separate line shows 4,622 shares held indirectly through an IRA, reflecting indirect ownership rather than a new market transaction.

Insider Trade Summary

Grant/Award: 4,410 shares

Grant/Award 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,410	$1.91	$8K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 64,396 shares (Direct); Common Stock — 4,622 shares (Indirect, Held by IRA)

Footnotes (1)

1. F1. Stock granted in lieu of cash for base salary

Key Figures

Stock grant: 4,410 shares Grant price: $1.91 per share Direct holdings after grant: 64,396 shares +1 more

4 metrics

Stock grant 4,410 shares Common stock granted in lieu of cash base salary

Grant price $1.91 per share Value used for the 4,410-share grant

Direct holdings after grant 64,396 shares Common stock held directly following the acquisition

Indirect IRA holdings 4,622 shares Common stock held indirectly in an IRA as a holding entry

Key Terms

Grant, award, or other acquisition, Held by IRA, stock granted in lieu of cash for base salary, indirect ownership

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Held by IRA financial

"nature_of_ownership: Held by IRA"

stock granted in lieu of cash for base salary financial

"Stock granted in lieu of cash for base salary"

indirect ownership financial

"ownership_type: indirect"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Imunon (IMNN) Executive Chairman Michael Tardugno report in this Form 4?

Michael H. Tardugno reported an updated position in Imunon common stock. He received 4,410 shares as a grant at $1.91 per share, bringing his direct holdings to 64,396 shares, plus 4,622 shares held indirectly through an IRA.

Was the Imunon (IMNN) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant, not an open-market trade. Tardugno received 4,410 shares of Imunon common stock as stock granted in lieu of cash base salary, coded as a grant or award (transaction code A), rather than buying or selling shares on the market.

How many Imunon (IMNN) shares does Michael Tardugno hold after this filing?

After the reported grant, Tardugno directly holds 64,396 Imunon common shares. The filing also shows 4,622 additional shares held indirectly in an IRA, providing a view of both his direct and indirect ownership positions in the company.

What is the price associated with the Imunon (IMNN) stock grant to Michael Tardugno?

The grant lists a price of $1.91 per share for the 4,410 Imunon common shares. This figure reflects the value used for the compensation grant recorded in lieu of cash base salary, not necessarily an open-market trading price.

How is Michael Tardugno’s indirect Imunon (IMNN) ownership structured in this Form 4?

The Form 4 identifies 4,622 Imunon common shares held indirectly through an IRA. This entry is marked as indirect ownership, indicating the shares are held in a retirement account rather than directly in his name, and is labeled as a holding entry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		A		4,410(1)	A	$1.91	64,396	D
Common Stock								4,622	I	Held by IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)